MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water

• Main Authors: Felke Steijns (Author), Nathalie Bracke (Author), Marjolijn Renard (Author), Julie De Backer (Author), Patrick Sips (Author), Nathan Debunne (Author), Evelien Wynendaele (Author), Frederick Verbeke (Author), Bart De Spiegeleer (Author), Laurence Campens (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Upregulation of the RAS-RAF-MEK-ERK-MAPK pathway is involved in the development of several human tumors, aortic aneurysms, atherosclerosis, and cardiomyopathy. Refametinib, a highly selective MEK-inhibitor, has already shown antineoplastic activity in phase II trials. Furthermore, it showed potency...